ArticleFrontiers in microbiology2019
Characterization of Subtilin L-Q11, a Novel Class I Bacteriocin Synthesized by
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Discovery and Characterization of a Novel Bacteriocin PFS-3 Targeting Multidrug-Resistant Escherichia coli.Probiotics and antimicrobial proteins · 2026Article
- Genomic insights and evaluation ofFrontiers in cellular and infection microbiology · 2026Article
- The Antibacterial Effect and Mechanism of a Bacteriocin Produced byJournal of microbiology and biotechnology · 2025Article
- Article
- Anti-listerial peptides from a marine3 Biotech · 2024Article
- Antimicrobial peptides from Bacillus spp. and strategies to enhance their yield.Applied microbiology and biotechnology · 2023Review
- Potential Impact of Combined Inhibition by Bacteriocins and Chemical Substances of Foodborne Pathogenic and Spoilage Bacteria: A Review.Foods (Basel, Switzerland) · 2023Review
- Evaluating the Translational Potential of Bacteriocins as an Alternative Treatment forAntibiotics (Basel, Switzerland) · 2023Review
- Bacteriocin Production by Bacillus Species: Isolation, Characterization, and Application.Probiotics and antimicrobial proteins · 2022Review
- Probiotic Characteristics and Antimicrobial Potential of a NativeMicroorganisms · 2022Article
- Discovery of a novel antibacterial protein CB6-C to target methicillin-resistant Staphylococcus aureus.Microbial cell factories · 2022Article
- A novel of new class II bacteriocin fromFrontiers in microbiology · 2022Article
- Targeted Antimicrobial Agents as Potential Tools for Modulating the Gut Microbiome.Frontiers in microbiology · 2022Review
- Bacteriocins: Properties and potential use as antimicrobials.Journal of clinical laboratory analysis · 2022Review
- Characterization and complete genome analysis of Bacillus velezensis CB6 revealed ATP synthase subunit α against foodborne pathogens.Archives of microbiology · 2021Article
- Characterization and Quantitative Determination of a Diverse Group of Bacillus subtilis subsp. subtilis NCIB 3610 Antibacterial Peptides.Probiotics and antimicrobial proteins · 2021Article
- Bacteriocin isolated from the natural inhabitant of Allium cepa against Staphylococcus aureus.World journal of microbiology & biotechnology · 2021Article
- Bacteriocins: Potential for Human Health.Oxidative medicine and cellular longevity · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriocins are peptides or proteins synthesized by bacterial ribosomes that show killing or inhibitory activities against different groups of bacteria. Bacteriocins are considered potential alternatives to traditional antibiotics, preservatives in pharmaceutical and food industries. A strain L-Q11 isolated from orchard soil was phylogenetically characterized as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.